Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name Imfinzi) is a treatment for non small cell lung cancer (NSCLC) but is also ...
Some results have been hidden because they may be inaccessible to you